An error occurred retrieving content to display, please try again.
Page not found (404)
Sorry - the page you requested could not be found.
Please choose a page from the navigation or try a website search above to find the information you need.
Toolkit
This trial did not show that tocilizumab was more effective than rituximab in patients with a B-cell-poor pathotype in the primary analysis; however, superiority was shown in most supplementary and secondary analyses using a molecular classification.
1 Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, UK
2 Institute of Experimental and Clinical Research, Université Catholique de Louvain, Louvain, Belgium
3 Clinical Trials Research Unit, University of Leeds, Leeds, UK
4 Blizard Institute, Barts Health NHS Trust, London, UK
5 Arthritis Unit, L’Institut d’Investigacions Biomèdiques, Barcelona, Spain
6 Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
7 King’s Clinical Trial Unit, King’s College London, London, UK
8 Instituto de Medicina Molecular, University of Lisbon, Lisbon, Portugal
9 Section of Rheumatology, Cardiff University School of Medicine, Cardiff University, Cardiff, UK
* Corresponding author Email: c.pitzalis@qmul.ac.uk
Funding: {{metadata.Funding}}
{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}
https://doi.org/{{metadata.DOI}}
Citation: {{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al.' : ''}} . {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})
Report Content
The full text of this issue is available as a PDF document from the Toolkit section on this page.
The full text of this issue is available as a PDF document from the Toolkit section on this page.
Responses to this report
No responses have been published.